Is there a need for ototoxicity monitoring in patients with HIV/AIDS?

African Journal of Pharmacy and Pharmacology

Volumn 4, Issue 9, 2010, Pages 574-579

  Katijah, Khoza Shangase ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Africa; Aminoglycosides; Antiretroviral drugs; Audiology; Hearing loss; Monitoring; Ototoxic

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; DIDANOSINE; ERYTHROMYCIN C; FLUCYTOSINE; HYDROXYUREA; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; VINCRISTINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; HEARING LOSS; HEARING TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IATROGENIC DISEASE; MORBIDITY; OPPORTUNISTIC INFECTION; OTOTOXICITY; PATIENT ASSESSMENT; PATIENT MONITORING; REVIEW; TINNITUS; VERTIGO;

EID: 78649896292     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Arslan E, Orzan E, Santarelli R (1999). Global Problem of Drug-Induced Hearing Loss. Annals New York Acad. Sci., 884: 1-14.
2. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, Wells C, Nunn P, Blanc L, Raviglione M (2006). Epidemiology of antituberculosis drug resistance (the global project on anti-tuberculosis drug resistance surveillance): An updated analysis. Lancet, 368(9553): 2142-2154.
3. Bankaitis AE (1996). Audiological changes attributable to HIV. Audiol. Today, 8(6): 14-16.
4. Bankaitis AF, Keith RW (1995). Audiologic changes associated with HIV infection. Ear Nose Throat J., 74: 353-359.
5. Bankaitis AE, Schountz T (1998). HIV-Related Ototoxicity. Semin. Hear., 19: 155-163.
6. Bateman C (2006). Taking ubhejane by the horn(s). S. Afr. Med. J., 96(5): 382.
7. Birchall M, Wight R, French P, Cockbain Z, Smith S (1992). Auditory function in patients infected with the Human Immunodeficiency Virus. Clin. Otolaryngol., 17: 117-121.
8. Campbell KCM (2007). Pharmacology and ototoxicity for Audiologists. United States: Thomson Delmar Learning.
9. Christensen LA, Morehouse CR, Powell TW, Alchediak T, Silio M (1998). Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings. J. Am. Acad. Audiol. 9: 292-298.
10. Clarke M, Dick J, Bogg L (2006). Cost-effectiveness analysis of an alternative tuberculosis management strategy for permanent farm dwellers in South Africa amidst health service contraction. Scandanavian J. Pub. Health, 34: 83-91.
11. Cohn A (1981). Etiology and pathology of disorders affecting hearing. In F.N. Martin (Ed). Medical audiology: Disorders of hearing. New Jersey: Prentice-Hall, Inc.
12. Colebunders R, Dipraetere K, Van Wanzeele P, Van Gehuchten S (1998). Deafness caused by didanosine. Microbiol. Infect. Dis., 17: 214-215.
13. Cummings CW (1993). Otolaryngology - Head and neck surgery. USA: Mosby-Yearbook.
14. Dorrington RE, Johnson LF, Bradshaw D, Daniel T (2006). The demographic impact of HIV/AIDS in South Africa. National and provincial indicators for 2006. Centre for Actuarial Research, South African Medical Research Council and Actuarial Society of South Africa, Cape Town.
15. Edmunds AL, Mudd PA, Kalkanis J, Campbell KCM, Rybak LP (2006). Inner ear ototoxicity. Retrieved from the Web October 10, 2006 http://www.emedicine.com
16. Fausti SA, Wilmington DJ, Helt PV, Konrad-Martin D (2005). Hearing and health care: the need for improved hearing loss prevention and hearing conservation practices. J. Rehab. Res. Dev., 42(4): 45-62.
17. Friedman JL, Noffsinger D (1998). Hearing loss associated with HIV/AIDS: Social, cultural, and political issues. Seminars in Hearing, 19: 205-214.
18. Gold S, Tami TA (1998). Otolaryngological Manifestations of HIV/AIDS. Semin. Hear., 19: 2.
19. Hall JW (2000). Handbook of otoacoustic emissions. San Diego: Singular Publishing Group.
20. Hawkins JE (1976). Drug ototoxicity. In: Keidel D. (Ed). Handbook of sensory physiology.(Vol. 5). Auditory system part 3: clinical and special topics. pp 707-748. Berlin: Springer.
21. Jackson GG, Arcieri G (1971). Ototoxicity of gentamicin in man. A survey and controlled analysis of clinical experience in the United States. J. Infect. Dis., 124: 130-137.
22. Kakuda TN (2000). Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Therapeut., 22(6): 685-708.
23. Kallail KJ, Downs DW, Schertz JW (2008). Communication disorders in individuals with HIV/AIDS. Kansas J. Med., 1(3).
24. Khoza K, Ross E (2002). Auditory function in a group of Adults infected with HIV/AIDS in an outpatient clinic in Gauteng, South Africa. S. Afr. J. Comm. Disorders 49: 17-27.
25. Khoza-Shangase K, Mupawose A, Mlangeni NP (2009). Ototoxic effects of tuberculosis treatments: How aware are patients? Afr. J. Pharm. Pharmacol., 3(8): 391-399.
26. Kohan D, Hammerschlag PE, Holliday RA (1990). Otologic disease in AIDS patients: CT correlation. Laryngoscope, 100: 1326-1330.
27. Lalwani AK, Sooy CD (1992). Otologic and neurologic manifestations of acquired immunodeficiency syndrome. Otolaryngol. Clin. N. Am., 25(6): 1183-1198.
28. Marra CM, Wechkin HA, Longstreth WT, Rees TS, Syapin CL, Gates GA (1997). Hearing loss and antiretroviral therapy in patients infected with HIV-1. Arch. Neurol., 54(4): 407-10.
29. Martinez OP, French MAH (1993). Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy. AIDS, 7: 901-902.
30. McArthur JC (1987). Neurologic manifestations of AIDS. Medicine, 66, 407-437.
31. McNaghten AD, Wan PT, Dworkin MS (2001). Correspondence: Prevalence of hearing loss in a cohort of HIV-Infected patients. Arch. Otolaryngol. Head Neck Surg., 127: 1516-1518.
32. Monte S, Fenwick JD, Monteiro EE (1997). Irreversible ototoxicity associated with zalcitabine. Intl. J. STDs AIDS, 8: 201-202.
33. Powderly WG, Klebert MK, Clifford DB (1990). Ototoxicity associated with dideoxycytidine. Lancet, 1: 1106.
34. Rey D, L'Heritier A, Lang JM (2002). Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV. Clin. Infect. Dis., 34: 417-418.
35. Schouten JT, Lockhart DW, Rees TS, Collier AC, Marra CM (2006). A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people. BMC Infect. Dis., 6: 28.
36. Seidman MD, Bai U, Khan MJ, Murphy MJ, Quirk WS, Castora FL, Hinojosa R (1996). Association of mitochondrial DNA deletions and cochlear pathology: a molecular biologic tool. Laryngoscope, 106: 777-783.
37. Simdon J, Watters D, Bartlett S, Connick E (2001). Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: A report of 3 possible cases and review of the literature. Clin. Infect. Dis., 32: 1623-1627.
38. Simdon J, Watters D, Bartlett S, Connick E (2001). Reply. Clin. Infect. Dis., 33: 2101-2102.
39. Smith A, MacKenzie I (1997). Hearing loss from ototoxics. WHO Drug Information, 11(1): 7-10.
40. Williams B (2001). Correspondence: Ototoxicity may be associated with protease inhibitor therapy. Clin. Infect. Dis., 33: 2100-2101.
41. Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Scott CA (2004). A(NRTIs, NNRTIs, and Fusion Inhibitors). Psychosomatics, 45(6).
42. Zuninga J (1999). Communication disorders and HIV disease. J. Intl. Ass. Phys. AIDS Care. Retrieved from the Web October 10, 2006 www.thebody.com/content/art12344.html.